Interested parties can also access the archived replay of the call webcast at www.aethlonmedical.com in the investor relations section under events & presentations.
Conference Call Details
What: Aethlon's Third Quarter 2017 Investor Conference Call and Audio Webcast
Date: Friday, February 10, 2017
Time: 4:30 p.m. Eastern Time
Live call: 844-836-8741
Audio Replay: 412-317-0088
About Aethlon Medical, Inc.
Aethlon Medical (Nasdaq: AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. The Aethlon Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens. Named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine, the Hemopurifier® has previously been administered to individuals infected with Ebola virus, Hepatitis C virus and the Human Immunodeficiency virus. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor neurological disorders. Aethlon is part of the Russell Microcap® Index. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.
Jim Frakes, CFO
858-459-7800 extension 3300
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-to-host-third-quarter-fiscal-2017-investor-call-on-february-10-2017-300402202.html
SOURCE Aethlon Medical, Inc.